METHODS:
Staph. epidermidis biofilm was grown on one centimeter diameter metallic discs of both medical grade stainless steel and titanium. The discs were treated in wells with the LFDCU for ten seconds at a three different power levels. The discs were stained with crystal violet and effluent was cultured. The study was repeated with hypochlorous acid as the device irrigant. Controls were performed.
RESULTS:
Biofilm was completely removed at all power levels. With saline irrigant, the effluent had viable planktonic bacteria. With hypochlorous acid irrigant, the effluent was sterile.
CONCLUSION:
The new LFDCU completely disperses biofilm from metallic discs at all energy levels. This suggests that biofilm can potentially be cleared from infected metallic implants even at low energy levels. In such cases, hypocholous acid device irrigation can remove any loosened bacteria. 
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THE USE OF LIPOSOMAL BUPIVACAINE IN PATIENTS UNDERGOING ABDOMINALLY-BASED AUTOLOGOUS AND IMPLANT-BASED BREAST RECONSTRUCTION
PURPOSE:
Federal mandates to reduce opioid use have placed analgesia management in the national conversation. Liposomal bupivacaine (LB) is an effective analgesic in the immediate postoperative period. This study explores the effect of LB on postoperative narcotic use, length of stay (LOS), and patient satisfaction in women undergoing autologous and implant-based breast reconstruction.
METHODS:
In our previous study, patients undergoing autologous (n=37) and implant-based reconstruction (n=20) who were injected with LB demonstrated significantly decreased total and oral narcotic use compared to controls. We subsequently changed our post-operative protocol and examined these changes over a 90-day implementation period. Patients undergoing abdominally-based autologous reconstruction (n=9) were transitioned to oral narcotics on post-operative day (POD) 2 rather than POD 3. Patient controlled analgesia (PCA) was eliminated from post-operative protocol in patients undergoing implant-based reconstruction (n=16). These patients were discharged on POD 1 rather than POD 2. Both patient groups were injected with LB and compared to historic controls. We examined LOS and patient satisfaction as primary outcomes within these populations. PURPOSE: Thrombosis of the vascular anastomosis or distal flap microcirculation is the most common cause of microvascular free tissue transfer failure. The large volume of existing literature has not yet reached a consensus on the ideal anticoagulation regimen to prevent thrombosis following microsurgery. Dabigatran, rivaroxaban, and apixaban are novel oral anticoagulants (NOACs) with an efficacy and safety profile equivalent or superior to standard agents such as warfarin. However, published reports of the use of NOACs in microsurgery are limited. This review aims to summarize current knowledge regarding the use of NOACs in microsurgery and provide clinical recommendations based on each agent's pharmacodynamics.
RESULTS:
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NOVEL ORAL ANTICOAGULANTS (NOACS) IN MICROSURGERY: A REVIEW
METHODS:
A systematic literature review was performed using the PubMed, Cochrane, and Google Scholar databases. Inclusion criteria were case reports and series of the use of NOACs in microsurgery.
RESULTS:
Five articles describing the use of NOACs in microsurgery were fully reviewed. A total of 32 patients undergoing 46 microsurgical procedures with either dabigatran or rivaroxaban were studied, with adverse effects occurring in 3 (6.5%). The most common adverse effect was hemorrhage, two of which were mild cases. No articles describing the use of apixaban were found. The risk of bleeding increased with concurrent administration of NSAIDs or other anticoagulants.
CONCLUSION:
Preoperative administration of NOACs in microsurgery is safe and has a low side-effect profile compared to standard anticoagulants. However, current administration protocols remain varied. Further research is warranted to elucidate the risks and benefits of NOACs in microsurgery, and to establish management guidelines for improved microsurgical outcomes. 
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TO OPERATE OR NOT
